SCHEMBL6172906

SCHEMBL6172906

c1ccc(-n2cnc(-c3cccnc3)c2)nc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 7/20 0.56
CYP2C19 P33261 4/20 0.56
CYP2E1 P05181 3/20 0.56
CYP2C9 P11712 3/20 0.56
CYP2B6 P20813 3/20 0.56
CYP3A4 P08684 5/20 0.54
CYP2D6 P10635 2/20 0.52
VHL P40337 1/20 0.49
CYP1A2 P05177 3/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
HSD17B10 Q99714 1/20 0.48
CLK4 Q9HAZ1 1/20 0.48
HSP90AA1 P07900 1/20 0.46
HSP90AB1 P08238 1/20 0.46
CYP19A1 P11511 1/20 0.45
COMT P21964 1/20 0.43
GRM5 P41594 1/20 0.43
PIM1 P11309 1/20 0.42
PIM2 Q9P1W9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5792405 0.93 CYP2A6 (0.49) CYP2A6CYP2C19CYP2E1CYP2C9CYP2B6
SCHEMBL5792876 0.92 CYP2A6 (0.48) CYP2A6CYP2C19CYP2E1CYP2C9CYP2B6
SCHEMBL2732909 0.82 CYP2A6 (0.50) CYP2A6CYP2C19CYP2E1CYP2C9CYP2B6
SCHEMBL2898239 0.81 CYP2A6 (0.52) CYP2A6CYP2C19CYP2E1CYP2C9CYP2B6
SCHEMBL2899672 0.78 CYP2A6 (0.49) CYP2A6CYP2C19CYP2E1CYP2C9CYP2B6
SCHEMBL6175240 0.78 GRM5 (0.45) TSHRCYP19A1GRM5PIM1ALDH1A1
SCHEMBL15293891 0.77 HSP90AA1 (0.52) CYP2A6CYP2C19CYP2E1CYP2C9CYP2B6
SCHEMBL5792550 0.77 NPC1 (0.60) HSD17B10GRM5NOX4NOX1ALDH1A1
SCHEMBL27699188 0.75 NPC1 (0.50) GRM5ALDH1A1NPC1RAB9A
SCHEMBL27699427 0.75 CYP2A6 (0.59) CYP2A6CYP2C19CYP2E1CYP2C9CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458385-A4 HETEROARYL SUBSTITUTED IMIDAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-12-21 EP claimed
US-20040259917-A1 Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5 COSFORD NICHOLAS D P (US) 2004-12-23 US claimed
EP-1458385-A2 HETEROARYL SUBSTITUTED IMIDAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 EP claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO claimed
WO-2003053922-A2 HETEROARYL SUBSTITUTED IMIDAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-07-03 WO claimed
EP-1458385-A4 HETEROARYL SUBSTITUTED IMIDAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-12-21 EP disclosed
US-20040259917-A1 Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5 COSFORD NICHOLAS D P (US) 2004-12-23 US disclosed
EP-1458385-A2 HETEROARYL SUBSTITUTED IMIDAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 EP disclosed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO disclosed
WO-2003053922-A2 HETEROARYL SUBSTITUTED IMIDAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259917-A1 Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C CYP2A6 2682/4885CYP2C19 1182/4885CYP2E1 2453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.